Multiplexperi Injection

Adult administration

The dosage and infusion rate should be determined based on fat removal and glucose metabolism capabilities, as well as the patient's condition, weight, and nutritional requirements. - Normal nutritional status or mild metabolic stress: 0.7 to 1.0 g/kg/day of amino acids (0.10 to 0.15 g nitrogen/kg) - Moderate to severe metabolic stress patients: 1.0 to 2.0 g/kg/day of amino acids.

This medication must be used strictly according to a doctor's instructions. When used concurrently with other medications containing calcium via intravenous injection, precipitation may occur between the drugs, so the same injection device should not be used at the same time. Those allergic to egg, soybean protein, or any components of this medication should not use it. Patients with specific electrolyte abnormalities such as hypernatremia, hyperchloremia, or hyperkalemia, or with severe kidney or liver dysfunction should avoid administration. Patients with certain conditions such as heart disease, heart failure, myasthenia gravis, or severe liver disease must carefully evaluate the need for this medication before administration. As it contains sodium bisulfite, it may trigger allergic reactions or asthma attacks in some patients, thus caution is required. During administration, blood glucose, liver function, kidney function, and electrolyte levels should be regularly monitored, and immediate action should be taken if any abnormal symptoms arise. The infusion rate should be slow, and special observation is needed for elderly or poorly nourished patients. In the case of overdose, symptoms such as acidosis, hypervolemia, electrolyte imbalance, and hyperglycemia may occur, necessitating an immediate cessation of administration and appropriate treatment. Pregnant or nursing women should use this medication cautiously, as its safety has not been established, based on a doctor's judgment. It is generally advised not to use this medication in children, especially infants under 2 years of age, as safety has not been confirmed. This medication should be administered slowly via intravenous infusion, and before administration, it should be ensured that the solution is clear and undamaged. Unused solution or equipment should not be reused and must be discarded, and sterile conditions should be maintained during mixing, with immediate use recommended. When storing, keep it in a sealed container to prevent air or moisture ingress, and it is important to maintain room temperature between 1 to 30 degrees Celsius. Avoid freezing to maintain the effectiveness and safety of the medication.

Serious side effects

• Possible allergic reactions such as urticaria, severe swelling (edema), chest tightness
• Respiratory issues such as dyspnea, asthma attacks, shock, and bronchoconstriction
• General malaise due to liver function dysfunction, hyperammonemia, coma
• Severe headaches
• Urine output decrease (oliguria, anuria), severe generalized edema, hypertension, and abnormal urination.

Mild side effects

• Nausea, vomiting, urticaria, rash, chest discomfort, palpitations, tachycardia, hypertension, chills, fever, headaches, urinary spasm, peripheral vascular dilation, hyper/hypotension
• Liver function abnormality (mild), hyperglycemia, hyperkalemia, increased BUN, hypophosphatemia, alkalosis, diabetes, osmotic diuresis and dehydration, rebound hypoglycemia, increased liver enzymes, vitamin deficiencies and excesses, electrolyte imbalances, thrombophlebitis
• Acidosis, cerebral edema

This medication should be stored in a sealed container to prevent air or moisture from entering. It is important to maintain a storage temperature of room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication’s effectiveness and safety for an extended period.

Appearance

A yellowish, clear liquid filled in a transparent plastic container divided internally by partitions.

Package unit

1100mL/bag (Solution A: 600mL, Solution B: 500mL), 550mL/bag (Solution A: 300mL, Solution B: 250mL)